

# IMMUNOCORE

targeting T cell receptors

PRESS RELEASE – IMMUNOCORE LIMITED

## Immunocore to Present at the Cowen and Company 37<sup>th</sup> Annual Healthcare Conference

(Oxford, UK, 28<sup>th</sup> February 2017) Immunocore Limited, a world-leading biotechnology company developing novel TCR-based biological drugs to treat cancer, infectious diseases and autoimmune diseases, announced today that it will present at the Cowen and Company 37<sup>th</sup> Annual Healthcare Conference in Boston, MA.

Eva-Lotta Allan, Immunocore's Chief Business Officer, is scheduled to present at The Boston Marriott Copley Place on Tuesday, March 7 at 5:00pm ET. Ms. Allan's presentation will provide an overview of the Company's world leading and highly innovative immuno-oncology technology, and an update on the progress of Immunocore's lead programme, IMCgp100.

- ENDS -

For more information, please contact:

### **Immunocore**

Eliot Forster, Chief Executive Officer/Eva-Lotta Allan, Chief Business Officer

T: +44 (0)1235 438600

E: [info@immunocore.com](mailto:info@immunocore.com)

### **Consilium Strategic Communications**

Mary-Jane Elliott/Jessica Hodgson/Chris Welsh/Laura Thornton

T: +44 (0)203 709 5700

E: [Immunocore@consilium-comms.com](mailto:Immunocore@consilium-comms.com)

### Notes for editors

### About Immunocore

Immunocore is a world-leading, independent biotechnology company using a unique T cell receptor (TCR) technology to target the most challenging disease areas. Immunocore's platform is based on its own soluble TCR ImmTAC<sup>®</sup> technology, which has been used to create a novel class of biologic drugs with the potential to treat multiple major indications including cancer, infectious diseases and autoimmune diseases. Unlike most treatment modalities, ImmTAC<sup>®</sup> molecules can address both extra and intracellular disease targets.

Across the pipeline, Immunocore has collaborations with Genentech, GlaxoSmithKline, MedImmune (the biologics division of AstraZeneca) and a co-discovery and co-development partnership with Lilly. Immunocore's wholly-owned lead programme, IMCgp100 is in a pivotal monotherapy trial in patients with metastatic uveal melanoma. The Company has also entered

# IMMUNOCORE

targeting T cell receptors

into combination trials with IMCgp100 in metastatic cutaneous melanoma, with MedImmune and Lilly.

Immunocore, headquartered near Oxford, UK with offices near Philadelphia, US, employs more than 300 staff and has a broad international investor base including Woodford Investment Management, Malin Corporation, Eli Lilly and Company, RTW Investments, Fidelity Management & Research Company as well as other private shareholders. For more information, please visit [www.immunocore.com](http://www.immunocore.com)